Nanoparticle immune treatment for SHH‑subtype medulloblastoma
Official title: Nanoformulated small molecule immunotherapy for SHH medulloblastoma
Funded at Univ of North Carolina Chapel Hill · NIH-11251558 · Data updated 2026-11-12
This project tests a tiny‑particle version of an immune drug designed to help children with SHH‑subtype medulloblastoma live longer with fewer lifelong side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| Award (this year) | $388,750 |
| NIH project number | 5R01NS125073-05 |
| Project ID | NIH-11251558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children with SHH‑subtype medulloblastoma, particularly those with recurrent disease or who are candidates for experimental immune therapy, would be the most relevant participants.
✕Less likely to help
Patients with non‑SHH medulloblastoma subtypes, other unrelated cancers, or those unable to access the study site likely would not benefit from this specific project.
What this research studies
The team is creating a nanoparticle formulation of an immune‑stimulating drug (resiquimod) to help it reach brain tumors and activate tumor‑associated immune cells in SHH medulloblastoma. The particles are designed to cross the blood–brain barrier and deliver the drug to TAMs that express TLR7/8. Researchers will test delivery, immune activation, and anti‑tumor effects in laboratory and model systems and explore combining the drug with cancer vaccines. The overall aim is to develop a safer, more effective immune approach to reduce toxic standard therapies for children.
Why it matters
Potential benefit: If successful, this could produce immune‑based treatments that better reach brain tumors and lower the long‑term cognitive and physical harms of current therapies for children.
How similar studies have gone: Related TLR7/8 drugs like resiquimod have been tested in clinical trials for melanoma, bladder cancer, and glioma, but a blood‑brain‑penetrant nanoparticle formulation for medulloblastoma remains novel and largely unproven in humans.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Sokolsky-Papkov, Marina — Univ of North Carolina Chapel Hill
- Study coordinator: Sokolsky-Papkov, Marina
Related research
Other NIH-funded projects on the same topics.
-
Immunotherapy for high-risk pediatric brain cancer using systems immunology
A program to understand why a dangerous form of childhood brain cancer resists immunotherapy and to develop new immune-based treatments for kids with Group 3 medulloblastoma.
-
Immune-based treatments for aggressive Group 3 medulloblastoma
Working to unlock the immune system to create new treatments for children with high-risk Group 3 medulloblastoma.
-
New treatment for a type of brain cancer in children
This study is testing a new treatment for children with SHH medulloblastoma, a type of brain cancer, using a special drug that helps the immune system fight the cancer while aiming to cause fewer side effects than current therapies.
-
Understanding how to improve immunotherapy for aggressive brain tumors in children
This study is looking at a tough type of brain tumor in kids called high-risk Group 3 medulloblastoma, and it's trying to find out how these tumors hide from the immune system so that new treatments can be created to help the immune system fight them better.
-
Using exosomes to improve immunotherapy for brain tumors in children
This study is testing a new treatment for children with medulloblastoma, a type of brain cancer, by using tiny particles from immune cells to help the body’s immune system fight the tumor more effectively while aiming to reduce side effects from standard treatments.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.